Sonoma Pharmaceuticals, Inc. quarterly report, Q3 FY2014

Business context and reporting period

Entity note: The supplied filing is a Form 10-Q for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc. It covers the fiscal quarter and nine months ended December 31, 2013; the comparative periods ended December 31, 2012. Unless stated otherwise, amounts below are in U.S. dollars.

Oculus develops and sells healthcare products based on its Microcyn technology, with products for wound care, dermatology, and animal healthcare, alongside laboratory testing services. Its products were marketed in 31 countries.

Financial performance and position

• Product gross margin was 67% for the quarter and 68% for the nine-month period, compared with 73% and 74%, respectively, in the prior-year periods. Lower margins in Mexico, including effects associated with the More Pharma transaction, were a key factor.
• For the nine months, operating cash flow was negative $3.401 million, investing cash flow was negative $0.428 million, and financing cash flow was negative $0.605 million. Cash declined $4.463 million to $3.437 million from March 31, 2013.
• At December 31, 2013, working capital was $2.573 million, total liabilities were $6.446 million, and stockholders’ equity was $3.397 million. Reported long-term debt, including its current portion, was approximately $49,000. The VLL loans and associated future interest were settled in December 2013.

Material changes versus prior comparable periods

• Quarterly revenue fell 7% year over year; nine-month revenue fell 11%. Product revenue declined 8% for the quarter and 12% for the nine months. U.S. and Mexico sales decreased, while Europe and other markets grew.
• Nine-month operating loss widened to $3.943 million from $1.992 million, and net loss increased to $3.722 million from $2.986 million. Research and development expense rose, including Ruthigen preclinical costs; lower Mexico selling costs partly offset higher Ruthigen expenses in selling, general and administrative costs.
• Quarterly net loss improved despite a larger operating loss, chiefly because of a $1.567 million gain from remeasurement of common stock issued under the VLL stock purchase agreement. This noncash fair-value gain was an unusual contributor to reported results.
• In December, the company issued 550,000 shares at $4.00 each, generating $2.002 million in net proceeds. VLL’s sale of shares under the earlier stock purchase agreement funded repayment of the remaining VLL debt and future interest.

Outlook, risks, and unusual items

• Management expected cash on hand to fund working capital, sales and marketing, and research and development through at least January 1, 2015. It also anticipated continuing losses and said additional capital may be needed; no new financing commitment was secured.
• Management expected Ruthigen-related research and development and administrative costs to decline over the following quarters. The filing provides no quantified revenue or earnings guidance.
• Oculus had $1.160 million of deferred Ruthigen offering costs on its balance sheet and reported a further $187,000 as expense. Reimbursement depended on Ruthigen’s intended IPO closing; the filing cautioned the IPO could be delayed or not occur.
• The company disclosed Nasdaq minimum-equity compliance concerns raised in November 2013. Equity was $3.397 million at December 31, 2013, above the $2.5 million threshold cited in the filing, but continued listing compliance remained a risk.
• Customer concentration was significant: for the nine months, three customers represented 37%, 25%, and 10% of net revenue. At period-end, three customers represented 43%, 21%, and 13% of net accounts receivable.
• Other disclosed exposures included legal disputes in Japan and Mexico, potential severance obligations under executive employment agreements, and a conditional $385,000 severance guarantee for Ruthigen’s former CEO approved after quarter-end.
• Product commercialization depends on regulatory approvals, partners, and market adoption. Oculus stated it lacked U.S. drug approval for antimicrobial or wound-healing indications; clinical trials for a U.S. drug pathway could be delayed without a funding partner or additional capital.

Investor verification priorities

1. Confirm the filing identity: this document is Oculus Innovative Sciences’ 10-Q, not a Sonoma Pharmaceuticals filing.
2. Review cash burn, the stated cash runway, and the availability and terms of any subsequent financing.
3. Check whether Ruthigen’s IPO closed and whether the $1.160 million deferred offering costs and other advances were reimbursed.
4. Assess the sustainability of revenue, gross margins, and customer relationships, particularly in the U.S. and Mexico and with concentrated customers.
5. Separate operating performance from the noncash VLL-related fair-value gain when evaluating the quarter’s lower net loss.
6. Confirm Nasdaq listing status and developments in the disclosed litigation and contingent obligations.